Use of this information to select and treat the patients at highest risk for progression earlier may help prevent irreversible liver damage and improve patient compliance with therapy. These results may also enable more cost-effective and timely demonstration of efficacy for new drug therapies by enriching trials with those individuals more likely to suffer from disease progression.

Kathy Ordonez